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Pharmacological interventions for chronic pain in children: An overview of systematic 
reviews 
Abstract  
We know little about the safety or efficacy of pharmacological medicines for children and 
adolescents with chronic pain, despite their common use. Our aim was to conduct an 
overview review of systematic reviews of pharmacological interventions that purport to 
reduce pain in children with chronic non-cancer pain or chronic cancer-related pain. We 
searched the Cochrane Database of Systematic Reviews, Medline, EMBASE and DARE for 
systematic reviews from inception to March 2018. We conducted reference and citation 
searches of included reviews. We included children (0-18 years of age) with chronic non-
cancer pain or chronic cancer-related pain. We extracted the review characteristics and 
primary outcomes of ≥30% participant-reported pain relief and patient global impression of 
change. We sifted 704 abstracts and included 23 systematic reviews investigating children 
with chronic non-cancer pain or chronic cancer-related pain. Seven of those 23 reviews 
included six trials that involved children with chronic non-cancer pain. There were no RCTs 
in reviews relating to reducing pain in chronic cancer-related pain. We were unable to 
combine data in a meta-analysis. Overall, the quality of evidence was very low and we have 
very little confidence in the effect estimates. The state of evidence of randomized controlled 
trials in this field is poor; we have no evidence from randomised controlled trials for 
pharmacological interventions in children with cancer-related pain, yet cannot deny 
individual children access to potential pain relief. Prospero ID: CRD42017081205. 
 
 
 
  
Introduction 
Pain is a common experience during childhood and adolescence.[41; 49] Pain lasting 
for longer than three months is defined as ‘chronic’, and is reported by approximately 25% of 
children and adolescents.[68] Around 5% of children report disabling chronic pain needing 
more intensive complex intervention.[41] Chronic pain can be disease or treatment-related 
(e.g., cancer, arthritis, sickle cell disease), of idiopathic origin (e.g., functional abdominal 
pain), or can persist after surgical intervention.[71] Chronic pain in childhood and 
adolescence, whatever its origin, is a major burden on individuals, families, and wider 
society.[33; 44; 73] Pain is also the most frequent symptom of patients with cancer, including 
in childhood,[21; 63; 98] and patients with cancer pain report lower quality of life.[1]     
Multi-disciplinary and biopsychosocial approaches to chronic pain management are 
generally advocated[53] and psychological[27; 28], and multidisciplinary rehabilitative[36] 
approaches to pain management have been described. The latter review included one 
randomised controlled trial and nine non-randomised trials. The authors found large 
improvements for disability, and small-to-moderate improvements for pain and depression 
across these trials.[36] Mixed findings have been identified for psychological interventions 
delivered to this population; small-to-moderate effects were identified for reducing pain 
intensity and for improving disability outcomes when delivered face-to-face. However, the 
quality of evidence across these reviews are low or very low, indicating that further evidence 
is likely to substantially change the estimate of effect.[27; 28] 
The first approach to manage pain is often pharmacological. There is, however, 
relatively little literature examining the efficacy and harm of pharmacological interventions 
in young people with chronic pain. This embarrassing lack of evidence for the 
pharmacological treatment of chronic pain in children was reported in 2003.[23; 40] In part 
the historical absence of research is due to the lack of testing of pharmacological 
interventions in children with chronic pain, and ethical difficulties concerning withholding 
medications from young people in pain. The USA Food and Drug Administration required all 
new drugs to be tested in children and adolescents under the Pediatric Research Equity Act in 
2003. However, few new chemical entities have been submitted for authorisation, so this 
regulation, and the equivalent in Europe, has had limited impact. Despite the lack of 
evidence, analgesics are regularly prescribed to children and adolescents with chronic pain 
and cancer pain.[87] There is a wealth of evidence in adults that is extrapolated to children, 
despite various warnings of the dangers of using such evidence to guide paediatric 
practice.[78]  
 In this overview we were interested in pharmacological interventions for the 
management of chronic pain in children and adolescents, in which the primary outcome was 
pain relief. Our aim was to provide a comprehensive summary of the evidence, appraise its 
quality, and set a path for the development of the field.  
 
Methods 
A protocol for this review was registered on PROSPERO (Prospero ID: 
CRD42018086900), in accordance with the Pain, Palliative, and Supportive Care (PaPaS) 
Cochrane group’s standard approach to conducting an overview review. This review was 
based on a an approach taken by PaPaS for an overview in adult neuropathic pain.[92] 
We searched the Cochrane Database of Systematic Reviews, Medline and Medline in 
process, EMBASE to March 2018, and DARE to issue 2 of 4, 2015 without date or language 
restrictions. Search strategies (eTable 1 in Supplement) were based on the strategies 
previously developed for the individual systematic reviews on this topic.[11-15; 22; 91] We 
required full peer-reviewed publication of reviews to be eligible for inclusion.  
We included systematic reviews investigating pharmacological treatments for children 
and adolescents (from birth to 18 years old) with chronic pain. Chronic pain (lasting for three 
months or longer) was defined within two categories: 
a. Chronic non-cancer pain (CNCP): pain not related to cancer and not relieved by 
disease-specific treatments. CNCP includes but is not limited to neuropathic pain, 
chronic musculoskeletal pain and chronic abdominal pain; or 
b. Chronic cancer-related pain (CCRP): pain directly related to cancer or its treatment. 
We only included systematic reviews that included randomised controlled trial(s) (RCTs), 
with or without blinding, and participant or observer-reported outcomes. We excluded 
children and adolescents taking pharmacological treatments for acute pain, headache, 
migraine, post-surgical pain, and pain associated with primary disease (with the exception of 
cancer). Disease-related pain conditions (e.g., rheumatoid arthritis, diabetes, inflammatory 
bowel disease) often have pain as a symptom, but may have different underlying mechanisms 
of their pain and disease modifying treatments. These conditions were beyond the scope of 
our review.  
Two review authors independently selected systematic reviews for inclusion and 
disagreements were resolved by discussion or advice from a third author. We included any 
systematic review that met our inclusion criteria, regardless of whether they found studies. 
Where the description regarding age was ambiguous or included predominantly adults (e.g., 
>15 years of age), we checked studies to see if children (≤18 years of age) were eligible or if 
the average age of the participants included in the systematic review was younger than 19 
years of age.  
Our primary outcomes included:  
1. Participant-reported pain relief of 30% or greater; 
2. Participant-reported pain relief of 50% or greater; 
3. Patient global impression of change much or very much improved. 
In the absence of self-reported pain, we considered the use of ‘other-reported’ pain, 
typically by an observer such as a parent, carer, or healthcare professional. 
Our secondary outcomes followed PedIMMPACT guidance.[57] These guidelines 
suggest core outcomes in paediatric chronic pain including:  
1. Carer global impression of change; 
2. Requirement for rescue analgesia; 
3. Sleep duration and quality; 
4. Acceptability of treatment; 
5. Physical functioning as defined by validated scales; 
6. Quality of life as defined by validated scales; 
7. Any adverse events; 
8. Withdrawals due to adverse events; 
9. Any serious adverse event.  
Serious adverse events typically include any untoward medical occurrence or effect 
that at any dose results in death, is life-threatening, requires hospitalisation or prolongation of 
existing hospitalisation, results in persistent or significant disability or incapacity, is an 
important medical event that may jeopardise the patient, or may require an intervention to 
prevent one of the above characteristics or consequences. 
Two review authors independently extracted characteristics and the GRADE 
assessments in individual reviews. We also extracted primary and secondary outcomes as 
specified in our protocol from each review, regardless of whether they were reported as 
primary or secondary outcomes in the included reviews. We evaluated the reviews using the 
quality rating scale AMSTAR-2 criteria.[81] Two authors independently rated each of the 
systematic reviews and any disagreement was resolved by consulting a third author.  
In line with our protocol, we used the amount and quality of evidence to report results 
in a hierarchical way, and followed a similar scheme used in other reviews. [60],[96] We split 
the available information into five groups, essentially according to the GRADE descriptors 
developed by the Evaluation of the Practice and Organisation of Care Cochrane Review 
Group (EPOC)[25], but also took into account the increasing evidence of the importance of 
small trial size, both because of random chance [7; 59; 85] and as an important source of 
bias.[16; 17; 26; 42; 66] In the first three groups, the amount and quality of evidence was 
insufficient to have confidence in the results. In the other two groups there was sufficient 
evidence to have confidence in the results (Table 1). 
We planned to extract data for groups 4 and 5 for each drug and pain condition. We 
planned to complete the following tasks for reviews that met the criteria of groups four or 
five; 1) report or calculate results from available data and report them in four ways: the risk 
ratio, the risk difference (percentage benefitting with intervention minus the percentage 
benefitting with placebo), the NNT (risk difference divided into 100), and the success 
rate.[58] 2) To calculate the maximum possible success as 100% minus placebo response, 
and drug specific success as active response minus placebo response; the success rate was 
expressed as a percentage of maximum possible response. 3) To collect available information 
on the number of patients experiencing any adverse event, the number with a serious adverse 
event, and the number withdrawing because of adverse events.  
We planned to conduct our own GRADE assessment of the main efficacy outcome in 
all reviews using EPOC criteria[25] (Table 1), irrespective of whether or not GRADE had 
been assessed in the included reviews, and the judgments made by authors. We planned to 
consider four sources of bias as being critically important because each of them alone could 
possibly change a positive result (“this intervention works”) to a negative (“this intervention 
does not work”). The four criteria needed for evidence to be high quality included 1) 
randomisation, 2) double-blind assessment of pain by patients, 3) avoidance of completer 
analyses or last observation carried forward (LOCF) data imputation if there were high 
adverse event withdrawals, and 4) having sufficient information in large studies to avoid 
random chance and small study bias effects. The absence of any one of these criteria could, in 
certain circumstances, reduce the quality assessment from high to very low quality. If there 
were no, or very little, evidence, we judged it to be of very low quality.[34] 
We narratively summarised the findings using the above judgements of confidence in 
the overall estimates of effect and harm for CNCP and CCRP separately. We summarised 
EPOC and GRADE judgements, included studies within the reviews, and AMSTAR 
judgements of the reviews. We were not able to synthesise data across reviews. We were 
unable to conduct planned subgroup analyses on the types of drugs and for children and 
adolescents with chronic cancer-related pain and chronic non-cancer pain due to lack of data.  
This review was part-funded by the UK National Institute for Health Research 
(NIHR), UK: NIHR Cochrane Programme Grant: 13/89/29 - Addressing the unmet need of 
chronic pain: providing the evidence for treatments of pain. The funder of the study had no 
role in study design, data collection, data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
 
Results 
We searched databases for systematic reviews investigating pharmacological 
interventions for children with CNCP or CCRP. We found 866 abstracts, and eight additional 
reviews through searching reference lists and conducting citation searches (Figure 1). 
Therefore we screened 704 abstracts after duplicates had been removed and read 47 reviews 
in full to assess eligibility for inclusion. Twenty-four of these reviews were excluded (eTable 
2 in Supplement). Consequently, we included 23 systematic reviews in this overview.[5; 6; 
11-15; 22; 35; 37; 45; 51; 56; 65; 70; 76; 79; 83; 90; 91; 93; 95; 97]  
We found 11 of these 23 included reviews investigated children with CNCP, 10 
investigated children with CCRP, one investigated children with either CNCP or CCRP, and 
one investigated children with life-limiting conditions. The reviews investigated a range of 
pharmacological treatments (Table 2). 
There were 16 of the 23 reviews that searched for children with CNCP or CCRP that 
fitted with EPOC evidence class 1; reviews that did not find any studies of children with 
CNCP or CCRP (see Table 2). Those reviews attempted to find trials on opioids, NSAIDs, or 
paracetamol in children with CCRP or opioids, paracetamol, or NSAIDs for children with 
CNCP, but failed to find any.  
The remaining seven reviews were classified as evidence class two (inadequate 
information: fewer than 200 participants in comparisons, in at least two studies). These 
reviews included 18 trials,[2-4; 8; 10; 38; 46-48; 50; 64; 69; 72; 75; 77; 80; 84; 99] of which 
six trials delivered analgesic drugs (Table 3). We have not grouped these trials by our 
predetermined outcomes, and most did not report the a-priori primary or secondary outcomes 
defined in our methods. Therefore, we have reported the closest corresponding outcomes in 
order to summarise the evidence in the most transparent way. We did not find any reviews 
that could be placed into EPOC classes 3, 4 or 5. 
We found two reviews that exclusively included trials that investigated the efficacy of 
antidepressants[14; 45], and a further three reviews that included other pharmacological 
interventions including antidepressants[51; 56; 76]. Cooper et al.,[14] included all 
antidepressant studies identified in the other four reviews, as well as newer trials and 
therefore, we will only discuss this review.  
Cooper et al.,[14] included four trials (272 participants) of antidepressants; three trials 
delivered amitriptyline and one study delivered citalopram to children. Cooper et al.,[14] 
judged the evidence for antidepressants for children with CNCP as very low across all of our 
outcomes, agreeing with other reviews of the use of antidepressants as adjuvants to pain 
treatment.[45; 51]  
Antidepressants vs. active control: One trial (n = 34) compared amitriptyline to an 
antiepileptic (gabapentin) control.[8] No data relating to pain reduction were available from 
this trial.  The decrease in pain intensity in each group exceeded the minimally important 
difference of 1/10 on the coloured analogue scale (decrease of 1.16 ± 2.26 for amitriptyline 
and 1.56 ± 2.27 for gabapentin). Three adverse events were reported, but the authors reported 
that they were not linked to the study drugs and there were no serious adverse events. 
Regarding secondary outcomes, children in both conditions reported better sleep quality. No 
other outcomes of interest to this overview were reported.  
Antidepressants vs. placebo control: Three trials (n = 238) compared amitriptyline or 
citalopram to placebo but none reported on our primary outcomes of 30 or 50% pain 
reduction.[4; 72; 77] However, each study reported no difference between groups on 
reduction of pain intensity and therefore there is no evidence of a beneficial effect of taking 
an antidepressant over a placebo for reducing pain symptoms. There was a low number of 
adverse events, and all studies reported that there were no serious adverse events. However, a 
small number of children withdrew from two[72; 77] of the three studies due to adverse 
events. With regards to the other secondary outcomes, there was insufficient evidence to 
combine one or more studies and no data could be combined into a meta-analysis. One study 
reported that the treatment group reported at least a 15% improvement in quality of life after 
treatment compared to the control group.[4] The authors[14] concluded that there was no 
evidence that antidepressants are effective or ineffective at treating CNCP.  
One review[15] including two studies[2; 8] of 141 children and adolescents with 
fibromyalgia or CRPS investigated antiepileptic drugs. The trials delivered either oral 
pregabalin vs. placebo[2] or gabapentin vs. amitriptyline (described earlier).[8] Cooper et 
al.,[15] judged all evidence to be very low quality, meaning that the true effect is likely to be 
substantially different, and the estimates could alter with the addition of new data.  
Antiepileptic drugs vs. active control: No data for our primary outcomes could be 
extracted when antiepileptic drugs were compared to an antidepressant comparator (see 
‘antidepressant vs. active control for description of study outcomes).[8]  
Antiepileptic drugs vs. placebo control: A study involving 107 participants did not 
find differences between groups for 30- or 50% reduction in pain when pregabalin was 
compared to placebo.[2] However, patient global impression of change was significantly 
higher in the pregabalin group compared to the placebo group. For secondary outcomes, 
similarly, carer global impression of change was much higher in the treatment compared to 
the placebo group. There was no significant difference over the course of the treatment period 
of 15 weeks for sleep quality and physical functioning. There were more adverse events and 
withdrawals due to adverse events in the treatment group compared to the placebo group. 
One serious adverse event was reported in the treatment group.[2] No other outcomes can be 
reported due to lack of data.  
 Serotonin (5HT2) antagonist vs. placebo control: A crossover trial (n = 14) 
administering pizotifen to a placebo control,[84] was included in three reviews.[56; 76; 90] 
This drug aims to prevent functional abdominal pain. The method of randomisation was not 
clear in this study. Nevertheless, in the absence of data from other trials, we report those 
findings here but advocate caution when interpreting the findings.  
None of our primary or secondary outcomes was reported in the trial.[84] However, 
children taking the serotonin antagonist reported eight fewer days of pain compared to 
control (but this was unclear from the study what duration this was over). No other validated 
measures were assessed although pain severity was significantly reduced and the Index of 
Misery (a non-validated scale) was marginally reduced in the intervention group.[84] Two 
patients reported side effects including increased appetite and drowsiness during the trial. The 
trial was stopped early as the trial drugs expired and there was evidence that patients 
preferred the intervention drug.    
 Two review authors independently rated the quality of included reviews with the 
AMSTAR2 quality rating system (eTable 3 in Supplement). Overall, the quality of included 
reviews was high, most likely a reflection of 19 out of 23 of the reviews being published as 
Cochrane reviews. We judged systematic reviews published outside of the Cochrane Library 
as being of lower quality, due to missing aspects such as the absence of a registered protocol 
prior to review production. Overall, we also found that some reviews did not report funding 
sources of individual trials. We could not judge a number of items because reviews were 
empty (i.e., did not include any studies eligible for inclusion in this review) and therefore we 
allocated these items as ‘not applicable’.   
 
Discussion 
Overall, there is no high-quality evidence for delivering any pharmacological 
intervention to a child or adolescent with chronic pain, and although the quality of the 
systematic reviews themselves is good, the quality of the evidence is very low, primarily due 
to the lack of data. Unusually, there are more reviews than trials. We found 23 reviews 
overall, of which 16 had no included studies with respect to children, and seven reviews 
included data from six randomised controlled trials that delivered analgesic drugs in children 
with CNCP. There were no randomised controlled trials of any pharmacological treatments 
for the management of cancer-related pain in children. 
Despite calls for more evidence,[23; 40] few attempts have been made to improve the 
number or quality of trials. Of the six trials in CNCP, the first was published in 1995 and the 
most recent in 2016. The average number of patients recruited to each trial was 66 (range 14 
to 115). At this rate of one trial of 19 patients entering into evidence every 3.5 years, it will 
take a conservative 1000 years to establish the evidence to substantially reduce the 
uncertainty around the estimates of effect for any pharmacological intervention for paediatric 
chronic pain management; 1000 years will not be enough to establish evidence in cancer 
pain.  
The paucity of results for pharmacological interventions for pain in children contrasts 
sharply with the very different situation in adults, where almost 300,000 patients have been 
identified in overviews or their equivalent. A network meta-analyses involved 146,524 adults 
with arthritis,[86] and 39,753 with acute postoperative pain.[61] Overview reviews also 
involve large numbers: 13,524 for opioids in cancer pain,[96] 37,143 in an overview of 
exercise therapy,[31] 2895 in an overview of TENS[32], 13,800 in an overview of 
antiepileptic drugs for neuropathic pain,[94] with an estimate of over 50,000 for all drugs for 
treating neuropathic pain. Further, the RCT evidence base for psychological interventions for 
children with chronic pain is also larger, including over 3,500 participants.[27; 28]  
 We need to better understand the barriers to producing evidence in paediatric chronic 
pain pharmacotherapy. There are practical and ethical considerations to conducting 
randomised controlled trials, but these are no different to other areas of paediatric 
pharmacological research where there is a need for more research.[54] There is a view that 
primary research is less important when one can extend evidence partially or completely (as 
supported by safety data) from adult medicine.[20; 82] However, the type and spectrum of 
chronic pain in young people differs from adults, and the influence of developmental 
considerations is likely to be substantial.[9] There is good evidence for efficacy and safety of 
pharmacological management in adult chronic pain, but these treatments are not as effective 
as commonly believed.[30] Without primary evidence we are ignorant as to whether the same 
pattern of findings is replicated or differs in children and adolescents. 
 Currently, there are no regulatory barriers to the off-licence prescription and use of 
most paediatric medicines, and there is common use of medicines licenced for adults in 
paediatric cases.[29; 89] Given the lack of market incentives for manufacturers, 
manufacturing and testing older drugs for young people does not attract the required 
resources.[43] In discussing the related problem of the lack of licensed analgesics for acute 
pain, researchers have reviewed attempts from the US Food and Drug Administration and the 
European Medicines Agency to incentivise manufacturers to undertake trials in children.[88] 
Better classification and assessment of chronic paediatric pain, with a focus on genetic and 
behavioural markers for pain that becomes chronic may provide methods of identifying sub-
groups of patients for whom novel analgesics could be developed.  
 In order to establish new comparative effectiveness research there is an urgent need to 
explore alternatives to the RCT, but alternatives that are able to manage biases reliably and 
convincingly, and which are ethically acceptable. For example, the use of micro-randomised 
trials is promising in which all members of a sample are exposed to the same treatment 
(avoiding ethical problems of an untreated group), but randomised to different features of that 
treatment (e.g., dose or length of administration). Target concentration strategies involving 
dose escalation[39] and the use of modelling and simulation[55] may reduce patient 
recruitment obligations. Similarly, advances in enriched enrolment randomised withdrawal 
(EERW) trials may be relevant. Such designs are particularly useful when placebo effects are 
likely to inflate the number needed to complete a trial.[77] Advances in single case designs, 
pioneered in psychology and rehabilitation, are especially relevant to the study of chronic 
cancer pain.[62] The benefits of single case designs are that they can capture an individual’s 
dynamic course of illness (and treatment response), individuals act as their own control, and 
findings can have greater ecological validity.[67] Further, mandatory reporting of adverse 
events and publishing of trial data in a repository should be required in every trial 
investigating pharmacological interventions.  
Finally, given the widespread use of off-licence prescribing in paediatric pain 
medicine and the absence of data concerning pain and its management, we need to focus on 
benefits of drugs as well as harms and harm-reduction. We know that millions of people are 
exposed to medicines that may not provide the desirable effect, but may also cause more 
harm than benefit.[19; 74] Further, the modern history of adult pain medicine is one of 
excessive exposure to ineffective medicines[52] which in some countries have caused major 
population harm[18] and in others excessive restriction.[24] The same dangers may be 
apparent in paediatric chronic pain. The better use of existing registers or the creation of new 
registers of analgesic use is needed. Where there is established infrastructure it may be 
possible to build research alliances and share treatment plans. We know of no national or 
trans-national prescription register that would enable outcome and/or adverse event 
monitoring specifically for medicines prescribed for paediatric chronic pain  
In conclusion, there is no high-quality evidence and we are uncertain of the efficacy 
or safety of any pharmacological treatments for paediatric chronic non-cancer pain. There is 
no evidence from RCTs for paediatric cancer pain. We have relatively high-quality 
systematic reviews of the few primary studies. More than ever before, we need to better 
understand the barriers to evidence production in childhood chronic pain, improve the 
classification and assessment of chronic pain, integrate clinical trials as part of routine 
clinical care, explore alternative RCT methods, and urgently establish the case for national or 
trans-national registries of patients treated for chronic pain, with a primary focus on analgesic 
medicines, benefits, harms and harm-reduction.   
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Table 1. Definitions of hierarchy of groups and EPOC criteria 
Group Definition 
GRADE of evidence (EPOC 
2015) 
1 Drugs and doses for which Cochrane 
Reviews found no information (very low 
quality evidence). 
Very low quality: this research 
does not provide a reliable 
indication of the likely effect. 
The likelihood that the effect 
will be substantially different† 
is very high. 
2 Drugs and doses for which Cochrane 
Reviews found inadequate information: 
fewer than 200 participants in 
comparisons, in at least two studies 
(very low quality evidence). 
Very low quality: this research 
does not provide a reliable 
indication of the likely effect. 
The likelihood that the effect 
will be substantially different† 
is very high. 
3 Drugs and doses for which Cochrane 
Reviews found evidence of effect, but 
where results were potentially subject to 
publication or other biases. We 
considered the number of additional 
participants needed in studies with zero 
effect (relative benefit of one) required 
to change the NNT for at least 50% 
maximum pain relief to an unacceptably 
high level (in this case the arbitrary NNT 
of 10). With fewer than 400 (equivalent 
to four studies with 100 participants per 
comparison, or 50 participants per 
group), we considered the results to be 
susceptible to publication bias and 
therefore unreliable (low quality 
evidence). We also considered data 
analyses with low numbers and subject 
to potential major bias to also be 
unreliable (low quality evidence). 
Low quality: this research 
provides some indication of 
the likely effect. However, the 
likelihood that it will be 
substantially different† is 
high. 
4 Drugs and doses for which Cochrane 
Reviews found evidence of no effect 
(high or moderate-quality evidence) or 
no evidence of effect (moderate-quality 
evidence): more than 200 participants in 
comparisons, but where there was no 
statistically significant difference from 
placebo. 
High-quality: this research 
provides a very good 
indication of the likely effect. 
The likelihood that the effect 
will be substantially different† 
is low. 
Moderate-quality: this 
research provides a good 
indication of the likely effect. 
The likelihood that the effect 
will be substantially different† 
is moderate. 
5 Drugs and doses for which Cochrane 
Reviews found evidence of effect, 
where results were reliable and not 
subject to potential publication bias 
(high quality evidence). 
High-quality: this research 
provides a very good 
indication of the likely effect. 
The likelihood that the effect 
will be substantially different† 
is low. 
   
† Substantially different: a large enough difference that it might affect a decision 
Table 2. Characteristics of included systematic reviews 
Review ID Condition Drug under 
review 
Control Number 
of 
included 
studies 
Number of 
Participants 
Number of 
studies 
eligible 
for 
inclusion 
Age Included 
in 
qualitative 
synthesis 
Bao, 20165 Chronic 
cancer pain 
Opioid 
(Hydromorphone) 
Active or 
placebo 
4 604 0 All 
adults 
No, only 
adults 
Beecham, 
20156 
Life limiting 
conditions 
Pharmacological 
interventions  
Active or 
placebo 
9 379 0 2-19 
years 
No, no 
cancer or 
CP 
Cooper, 201714 Chronic non-
cancer pain 
Antidepressants Active or 
placebo 
4 272 4 6-18 
years 
Yes 
Cooper, 201715 Chronic non-
cancer pain 
Antiepileptic Active or 
placebo 
2 141 2 7-18 
years 
Yes 
Cooper, 201713 Chronic 
cancer pain 
NSAIDS Active or 
placebo 
0 0 0 N/A No, empty 
review 
Cooper, 201712 Chronic non-
cancer pain 
Opioids Active or 
placebo 
0 0 0 Childre
n 
No, empty 
review 
Cooper, 201711 Chronic non-
cancer pain 
Paracetamol Active or 
placebo 
0 0 0 Childre
n 
No, empty 
review 
Eccleston, 
201722 
Chronic non-
cancer pain 
NSAIDS Active or 
placebo 
7 1074 0 2-17 
years 
No, no 
cancer or 
CP 
Hadley, 201335 Chronic 
cancer pain 
Opioid 
(Transdermal 
fentanyl) 
Active or 
placebo 
9 1244 0 18-91 
years 
No, only 
adults 
Heintjes, 
200437 
Patellofemoral 
pain 
syndrome 
Pharmacological 
interventions 
Active or 
placebo 
or no 
treatment 
8 290 0 
 
Mean 
age is 
>18 
No, only 
adults 
(lower age 
15 years) 
Kaminski, Abdominal Antidepressants Active or 2 123 2 8-18 Yes 
201145 pain placebo years 
Korterink, 
201551 
Abdominal 
pain 
Pharmacological 
interventions 
Active or 
placebo 
or no 
treatment 
6 388 6 4.5-18 
years 
Yes 
Martin, 201756 Abdominal 
pain 
Any drug Active or 
placebo 
or no 
treatment 
16 1024 0 5-18 
years 
Yes 
Nicholson, 
201765 
Chronic 
cancer pain 
Opioid 
(Methadone) 
Active or 
placebo 
6 388 0 18-87 
years 
No, only 
adults 
Quigley, 200370 Chronic 
cancer and 
non-cancer 
pain 
Opioid 
(Hydromorphone) 
Active or 
placebo 
43 2725 0 Lifespa
n, but 
mostly 
adults 
or 
post-op 
kids 
No 
children 
with 
chronic 
pain 
studies 
Saps, 201576 Abdominal 
pain 
Pharmacological 
interventions  
Placebo 7 325 7 4-18 
years 
Yes 
Schmidt-
Hansen, 201679 
Chronic 
cancer pain 
Opioid 
(Buprenorphine) 
Active or 
placebo 
19 1421 0 49.1-
67.16 
years 
No, only 
adults 
Straube, 201483 Chronic 
cancer pain 
Opioid (Codeine)  Active or 
placebo 
15 721 0 51-64 
years 
No, only 
adults 
Weydert, 
200390 
Abdominal 
pain 
Pharmacological 
interventions  
Unknown 10 362 2 3-18 
years 
Yes 
Wiffen, 201791 Chronic 
cancer pain 
Opioids Active or 
placebo 
0 0 0 Childre
n 
No, empty 
review 
Wiffen, 201697 Chronic 
cancer pain 
Opioid (Morphine)  Active or 
placebo 
62 4241 0  Think they 
are all 
adults - 
 
  
check with 
PW 
Wiffen, 201795 Chronic 
cancer pain 
Paracetamol Active or 
placebo 
3 122 0 56-72 
years 
No, only 
adults 
Wiffen, 201793 Chronic 
cancer pain 
Opioid (Tramadol) Active or 
placebo 
10 958 0 Adults No, only 
adults 
Table 3. Characteristics of individual randomised controlled trials 
 
RCT ID Drug name Drug class Pain condition Review ID Included in 
overview? 
Arnold, 20162 
 
Pregabalin Anti-epileptic Fibromyalgia Cooper 201224  Yes 
 
Asgarshirazi, 
20153 
Peppermint oil Antispasmodic  RAP Martin 201751 No 
Bahar, 20084 Amitriptyline 
 
Anti-depressant 
 
RAP Cooper 201223  
Kaminski 201149 
Korterink 201550 
Martin 201751 
Saps 201554 
Yes 
Brown, 20168 Amitriptyline; 
Gabapentin 
Anti-depressant; 
Anti-epileptic 
CRPS Cooper 201223  
Cooper 201224  
Yes 
Collins, 201110 Rifaximin Antibiotic RAP Martin 201751 
Saps 201554 
No 
Heyland, 201238 Trimethoprim 
and 
sulfamethoxazole 
Antibiotic RAP Martin 201751 No 
Karabulut, 201346 Trimebutine 
maleate 
Antimuscarinic  RAP Martin 201751 No 
Karunanayake, 
201547 
Domperidone Dopamine d₂  
receptor 
antagonist  
RAP Martin 201751 No 
Khoshoo 200648 PEG 3350 vs 
PEG 3350 + 
tegaserod 
Laxative RAP Korterink 201550 
Martin 201751 
No 
Kline, 200150 Peppermint oil Alternative RAP Korterink 201550 
Martin 201751 
Saps 201554 
No 
Narang, 201564 Drotaverine Antispasmodic RAP Martin 201751 No 
Pourmmoghaddas
, 201469 
Mebeverine Antispasmodic RAP Martin 201751 No 
Roohafza, 201472 Citalopram Anti-depressant RAP Cooper 201223  
Martin 201751 
Yes 
Sadeghian, 
200875 
Cyproheptadine Antihistamines RAP Korterink 201550 
Martin 201751 
No 
Saps, 200977 Amitriptyline Anti-depressant RAP Cooper 201223  
Kaminski 201149 
Korterink 201550 
Martin 201751 
Saps 201554 
Yes 
See, 200180 Famotidine Histamine RAP Korterink 201550 
Saps 201554 
Weydert 200357 
No 
Symon, 199584 Pizotifen Serotonin 
antagonist 
RAP Martin 201751 
Saps 201554 
Weydert 200357 
Yes 
Zyback, 201699 Melatonin Hormone RAP Martin 201751 No 
RAP - recurrent abdominal pain; CRPS – complex regional pain syndrome 
 
 
 
 
  
eTable 1. Search strategies for all databases 
 
CDSR & DARE (COCHRANE LIBRARY) 
#1 MeSH descriptor: [Pain] explode all trees 
#2 pain:ti  (Word variations have been searched) 
#3 #1 or #2  
#4 MeSH descriptor: [Child, Preschool] explode all trees 
#5 MeSH descriptor: [Child] explode all trees 
#6 MeSH descriptor: [Adolescent] explode all trees or MeSH descriptor: [Infant] 
explode all trees 
#7 (child* or infant* or baby or babies* or boy* or girl* or adolescen* or teen* or 
toddler* or preschooler* or pre-schooler*):ti  (Word variations have been searched) 
#8 #4 or #5 or #6 or #7  
#9 #3 and #8  
#10 MeSH descriptor: [Narcotics] this term only 
#11 MeSH descriptor: [Analgesics, Opioid] this term only 
#12 (morphine or buprenorphine or codeine or dextromoramide or diphenoxylate 
or dipipanone or dextropropoxyphene or propoxyphene or diamorphine or 
dihydrocodeine or alfentanil or fentanyl or remifentanil or meptazinol or methadone 
or nalbuphine or oxycodone or papaveretum or pentazocine or meperidine or 
pethidine or phenazocine or hydrocodone or hydromorphone or levorphanol or 
oxymorphone or butorphanol or dezocine or sufentanil or ketobemidone):ti  (Word 
variations have been searched) 
#13 #10 or #11 or #12  
#14 MeSH descriptor: [Antidepressive Agents] explode all trees 
#15 (amitriptyline or clomipramine or doxepin or imipramine or nortriptyline or 
trimipramine or mianserin or trazadone or citalopram or fluoxetine or fluvoxamine or 
sertraline):ti  (Word variations have been searched) 
#16 MeSH descriptor: [Anticonvulsants] explode all trees 
#17 (carbamazepine or clobazam or clonazepam or ethosuximide or gabapentin 
or lacosamide or lamotrigine or levetiracetam or oxcarbazepine or phenytoin or 
pregabalin or rufinamide or topiramate or valproate or vigabatrin or zonisamide):ti  
(Word variations have been searched) 
#18 MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees 
#19 NSAID*:ti  (Word variations have been searched) 
#20 "non-steroidal anti-inflammatory drug*":ti  (Word variations have been 
searched) 
#21 (ibuprofen or aspirin or naproxen or fenoprofen or ketoprofen or tiaprofenic 
acid or diclofenac or aceclofenac or etodolac or indometacin or mefenamic acid or 
meloxicam or nabumeton or phenylbutazone or piroxicam or sulindac or tenoxicam 
or tolfenamic acid or ketorolac or parecoxib or celecoxib or etoricoxib):ti  (Word 
variations have been searched) 
#22 MeSH descriptor: [Acetaminophen] this term only 
#23 (acetaminophen or paracetamol or Calpol or Panadol or Tylenol):ti  (Word 
variations have been searched) 
#24 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23  
#27 #9 and #24 
 
 
MEDLINE (OVID) 
1     exp PAIN/ (353922) 
2     pain.tw. (518812) 
3     1 or 2 (665398) 
4     exp Infant/ (1056001) 
5     adolescent/ or exp child/ (2754553) 
6     (child* or infant* or baby or babies* or boy* or girl* or adolescen* or teen* or 
toddler* or preschooler* or pre-schooler*).tw. (1710613) 
7     4 or 5 or 6 (3644325) 
8     3 and 7 (116375) 
9     NARCOTICS/ (15842) 
10     Analgesics, Opioid/ (36058) 
11     (morphine or buprenorphine or codeine or dextromoramide or diphenoxylate or 
dipipanone or dextropropoxyphene or propoxyphene or diamorphine or 
dihydrocodeine or alfentanil or fentanyl or remifentanil or meptazinol or methadone 
or nalbuphine or oxycodone or papaveretum or pentazocine or meperidine or 
pethidine or phenazocine or hydrocodone or hydromorphone or levorphanol or 
oxymorphone or butorphanol or dezocine or sufentanil or ketobemidone).tw. (91576) 
12     9 or 10 or 11 (117345) 
13     exp Antidepressive Agents/ (134160) 
14     (amitriptyline or clomipramine or doxepin or imipramine or nortriptyline or 
trimipramine or mianserin or trazadone or citalopram or fluoxetine or fluvoxamine or 
sertraline).tw. (36037) 
15     exp ANTICONVULSANTS/ (130253) 
16     (carbamazepine or clobazam or clonazepam or ethosuximide or gabapentin or 
lacosamide or lamotrigine or levetiracetam or oxcarbazepine or phenytoin or 
pregabalin or rufinamide or topiramate or valproate or vigabatrin or zonisamide).tw. 
(45933) 
17     exp Anti-Inflammatory Agents, Non-Steroidal/ (182886) 
18     NSAID*.tw. (21705) 
19     "non-steroidal anti-inflammatory drug*".tw. (12142) 
20     (ibuprofen or aspirin or naproxen or fenoprofen or ketoprofen or tiaprofenic acid 
or diclofenac or aceclofenac or etodolac or indometacin or mefenamic acid or 
meloxicam or nabumeton or phenylbutazone or piroxicam or sulindac or tenoxicam 
or tolfenamic acid or ketorolac or parecoxib or celecoxib or etoricoxib).tw. (84132) 
21     ACETAMINOPHEN/ (16380) 
22     (acetaminophen or paracetamol or Calpol or Panadol or Tylenol).tw. (21443) 
23     12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 (610504) 
24     8 and 23 (11308) 
25     limit 24 to humans (10871) 
26     meta-analysis.pt. (85095) 
27     meta-analysis.sh. (85095) 
28     (meta-analys$ or meta analys$ or metaanalys$).tw,sh. (144406) 
29     (systematic$ adj5 review$).tw,sh. (121923) 
30     (systematic$ adj5 overview$).tw,sh. (1551) 
31     (quantitativ$ adj5 review$).tw,sh. (6343) 
32     (quantitativ$ adj5 overview$).tw,sh. (266) 
33     (quantitativ$ adj5 synthesis$).tw,sh. (2062) 
34     (methodologic$ adj5 review$).tw,sh. (4951) 
35     (methodologic$ adj5 overview$).tw,sh. (330) 
36     (integrative research review$ or research integration).tw. (118) 
37     or/26-36 (225428) 
38     25 and 37 (271) 
 
EMBASE (OVID) 
1     exp PAIN/ (1123664) 
2     pain.tw. (765050) 
3     1 or 2 (1344895) 
4     *NARCOTIC AGENT/ (4160) 
5     *Narcotic Analgesic Agent/ (6991) 
6     (morphine or buprenorphine or codeine or dextromoramide or diphenoxylate or 
dipipanone or dextropropoxyphene or propoxyphene or diamorphine or 
dihydrocodeine or alfentanil or fentanyl or remifentanil or meptazinol or methadone 
or nalbuphine or oxycodone or papaveretum or pentazocine or meperidine or 
pethidine or phenazocine or hydrocodone or hydromorphone or levorphanol or 
oxymorphone or butorphanol or dezocine or sufentanil or ketobemidone).tw. 
(124203) 
7     4 or 5 or 6 (132140) 
8     exp *Antidepressant Agent/ (190291) 
9     (amitriptyline or clomipramine or doxepin or imipramine or nortriptyline or 
trimipramine or mianserin or trazadone or citalopram or fluoxetine or fluvoxamine or 
sertraline).tw. (47626) 
10     exp *ANTICONVULSIVE AGENT/ (153682) 
11     (carbamazepine or clobazam or clonazepam or ethosuximide or gabapentin or 
lacosamide or lamotrigine or levetiracetam or oxcarbazepine or phenytoin or 
pregabalin or rufinamide or topiramate or valproate or vigabatrin or zonisamide).tw. 
(69681) 
12     exp *nonsteroid antiinflammatory agent/ (234761) 
13     NSAID*.tw. (37057) 
14     "non-steroidal anti-inflammatory drug*".tw. (16827) 
15     (ibuprofen or aspirin or naproxen or fenoprofen or ketoprofen or tiaprofenic acid 
or diclofenac or aceclofenac or etodolac or indometacin or mefenamic acid or 
meloxicam or nabumeton or phenylbutazone or piroxicam or sulindac or tenoxicam 
or tolfenamic acid or ketorolac or parecoxib or celecoxib or etoricoxib).tw. (166661) 
16     *paracetamol/ (23397) 
17     (acetaminophen or paracetamol or Calpol or Panadol or Tylenol).tw. (35301) 
18     7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (830513) 
19     *review/ (1793) 
20     (literature adj3 review$).ti,ab. (293221) 
21     *meta analysis/ or *network meta analysis*/ (14769) 
22     *Systematic Review/ (11979) 
23     (systematic$ adj2 (review$ or overview)).ti,ab. (154930) 
24     (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanal$).ti,ab. 
(162084) 
25     or/19-24 (516440) 
26     *child/ or *boy/ or *girl/ or *toddler/ (99119) 
27     *preschool child/ (2674) 
28     *infant/ or *baby/ or *high risk infant/ or *hospitalized infant/ or *newborn/ 
(62266) 
29     *adolescent/ or *hospitalized adolescent/ (29168) 
30     (child* or infant* or baby or babies* or boy* or girl* or adolescen* or teen* or 
toddler* or preschooler* or pre-schooler*).tw. (2162280) 
31     26 or 27 or 28 or 29 or 30 (2201713) 
32     3 and 18 and 25 and 31 (577) 
33     limit 32 to human (563) 
 
   
   
44 
eTable 2: Excluded review references and reasons 
 
Excluded review reference Reason for exclusion 
Ahn, J. S., Lin, J., Ogawa, S., Yuan, C., O’Brien, T., Le, B. H., Bothwell, A. M., Moon, 
H., Hadjiat, Y., & Ganapathi, A. (2017). Transdermal buprenorphine and fentanyl 
patches in cancer pain: a network systematic review. Journal of pain research, 10, 
1963. 
Review does not include children 
Anonymous. (2006). Effective medications for juvenile idiopathic arthritis. Journal of the 
National Medical Association, 98(1), 101-102.  
Review is not a full peer-reviewed 
systematic review 
Davis, M. P. (2011). Fentanyl for breakthrough pain: a systematic review. Expert 
Review of Neurotherapeutics, 11(8), 1197-1216. doi: 10.1586/ern.11.63 
Review does not include chronic 
cancer or non-cancer pain 
de Martino, M., & Chiarugi, A. (2015). Recent Advances in Pediatric Use of Oral 
Paracetamol in Fever and Pain Management. Pain and Therapy, 4(2), 149-168. doi: 
10.1007/s40122-015-0040-z 
Review does not include chronic 
cancer or non-cancer pain 
Devulder, J., Richarz, U., & Nataraja, S. H. (2005). Impact of long-term use of opioids 
on quality of life in patients with chronic, non-malignant pain. Current Medical Research 
& Opinion, 21(10), 1555-1568.  
Review does not include children 
Dunlop, R., & Bennett Kyle, C. L. B. (2014). Pain management for sickle cell disease in 
children and adults. Cochrane Database of Systematic Reviews, Volume(4). 
doi:10.1002/14651858.CD003350.pub3 
Review does not include chronic 
cancer or non-cancer pain 
Egunsola, O., Choonara, I., & Sammons, H. M. (2015). Safety of lamotrigine in 
paediatrics: a systematic review. BMJ Open, 5(6), e007711. 
doi:https://dx.doi.org/10.1136/bmjopen-2015-007711 
Review does not include chronic 
cancer or non-cancer pain 
Fedorowicz, Z., Nasser, M., Jagannath, V. A., Beaman, J. H., Ejaz, K., & van Zuuren, 
E. J. (2012). Beta2-adrenoceptor agonists for dysmenorrhoea. Cochrane Database of 
Systematic Reviews(5), CD008585. doi:10.1002/14651858.CD008585.pub2 
Review does not include children 
Foisy, M., Ali, S., Geist, R., Weinstein, M., Michail, S., & Thakkar, K. (2011). The 
Cochrane Library and the treatment of chronic abdominal pain in children and 
adolescents: an overview of reviews. Evidence Based Child Health: A Cochrane 
Review Journal, 6(4), 1027-1043. 
Review is not a full peer-reviewed 
systematic review 
Frampton, J. E., & Keating, G. M. (2007). Celecoxib: A review of its use in the 
management of arthritis and acute pain. Drugs, 67(16), 2433-2472.  
Review is not a full peer-reviewed 
systematic review 
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Goldstein, L. H., Berlin, M., Berkovitch, M., & Kozer, E. (2008). Effectiveness of oral vs 
rectal acetaminophen: a meta-analysis. Archives of Pediatrics & Adolescent Medicine, 
162(11), 1042-1046. doi: 10.1001/archpedi.162.11.1042 
Review is not include chronic cancer or 
non-cancer pain 
Huber, A. M., Tomlinson, G. A., Koren, G., & Feldman, B. M. (2007). Amitriptyline to 
relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of 
multiple N-of-1 clinical trials. Journal of Rheumatology, 34(5), 1125-1132.  
Review is not a full peer-reviewed 
systematic review 
Huertas-Ceballos, A., Logan, S., Bennett, C., & Macarthur, C. (2008). Pharmacological 
interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in 
childhood. Cochrane Database of Systematic Reviews(1), CD003017. doi: 
10.1002/14651858.CD003017.pub2 
Cochrane review that has been 
updated 
Kahan, M., Wilson, L., Mailis-Gagnon, A., & Srivastava, A. (2011). Canadian guideline 
for safe and effective use of opioids for chronic noncancer pain. Canadian Family 
Physician, 57(11), 1269-1276. 
Review is not a full peer-reviewed 
systematic review 
Lang, B. C., Yang, C.-S., Zhang, L.-L., Zhang, W.-S., & Fu, Y.-Z. (2017). Efficacy of 
lidocaine on preventing incidence and severity of pain associated with propofol using in 
pediatric patients: A PRISMA-compliant meta-analysis of randomized controlled trials. 
Medicine, 96(11), e6320. doi: 10.1097/MD.0000000000006320 
Review does not include chronic 
cancer or non-cancer pain 
Marjoribanks, J., Proctor, M., Farquhar, C., & Derks, R. S. (2010). Nonsteroidal anti-
inflammatory drugs for dysmenorrhoea. Cochrane 
Database of Systematic Reviews Issue 1. Art. No.: CD001751. DOI: 
10.1002/14651858.CD001751.pub2. 
Review does not include children  
Meremikwu, M. M., & Okomo, U. (2011). Sickle cell disease. Clinical Evidence, 14, 14.  Review does not include chronic 
cancer or non-cancer pain 
Meremikwu, M. M. (2009). Sickle cell disease. Clinical Evidence, 27, 27.  Review does not include chronic 
cancer or non-cancer pain 
Mudd, S. (2011). Intranasal fentanyl for pain management in children: a systematic 
review of the literature. Journal of Pediatric Health Care, 25(5), 316-322. doi: 
10.1016/j.pedhc.2010.04.011 
Review does not include chronic 
cancer or non-cancer pain 
Nuesch, E., Hauser, W., Bernardy, K., Barth, J., & Juni, P. (2013). Comparative efficacy 
of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: 
network meta-analysis. Annals of the Rheumatic Diseases, 72(6), 955-962. doi: 
10.1136/annrheumdis-2011-201249 
Review does not include children 
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Persad, R., Harvey, K., & Becker, L. (2009). The Cochrane Library and Recurrent 
Abdominal Pain in Children: An Overview of Reviews. Evidence Based Child Health: A 
Cochrane Review Journal, 4(1), 4-14. 
Review is not a full peer-reviewed 
systematic review 
Pierce, C. A., & Voss, B. (2010). Efficacy and safety of ibuprofen and acetaminophen in 
children and adults: a meta-analysis and qualitative review. Annals of 
Pharmacotherapy, 44(3), 489-506. doi:https://dx.doi.org/10.1345/aph.1M332 
Review does not include chronic 
cancer or non-cancer pain 
Porzio, F. (1993). Meta-analysis of two double-blind comparative studies with the 
sustained-release form of etodolac in rheumatoid arthritis. Rheumatology International, 
13(2 Suppl), S25-30.  
Review does not include children 
Quigley, C. (2002). Hydromorphone for acute and chronic pain. Cochrane Database of 
Systematic Reviews(1), CD003447.  
Cochrane review that has been 
updated 
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eTable 3: Quality ratings for included reviews  
 AMSTAR-2 item 
 1 2 3 4 5 6 7 8 
Bao, 20165 Yes Yes Yes Yes Yes Yes Yes Yes 
Beecham, 20156 Yes Yes Yes Partial yes Yes Yes Yes Yes 
Cooper, 201714 Yes Yes Yes Yes Yes Yes Yes Yes 
Cooper, 201715 Yes Yes Yes Yes Yes Yes Yes Yes 
Cooper, 201713 Yes Yes Yes Yes Yes N/A Yes N/A 
Cooper, 201712 Yes Yes Yes Yes Yes N/A Yes N/A 
Cooper, 201711 Yes Yes Yes Yes Yes N/A Yes N/A 
Eccleston, 201722 Yes Yes Yes Yes Yes N/A Yes Yes 
Hadley, 201335 Yes Yes Yes Yes Yes Yes Yes Yes 
Heintjes, 200437 Yes Yes Yes Partial yes Yes Yes Yes Yes  
Kaminski, 201144 Yes Yes Yes Partial yes Yes Yes Yes Partial yes 
Korterink, 201551 Yes No No No Yes No No Yes 
Martin, 201756 Yes Yes Yes Yes Yes Yes Yes Yes 
Nicholson, 201765 Yes Partial yes Yes Yes Yes No Yes Partial yes 
Quigley, 200370 Yes No No Partial Yes No No No Yes 
Saps, 201576 Yes No No No Yes Yes No No 
Schmidt-Hanswen, 201679 Yes Yes Yes Partial Yes Yes Yes No Yes 
Straube, 201483 Yes Yes Yes Partial Yes Yes Yes Yes Partial yes 
Weydert, 200390 No No No No No No No Partial yes 
Wiffen, 201791 Yes Yes Yes Yes Yes N/A Yes N/A 
Wiffen, 201697 Yes No Yes Partial Yes No Yes Yes Yes 
Wiffen, 201795 Yes Yes Yes Yes Yes Yes Yes Partial yes 
Wiffen, 201793 Yes Yes Yes Yes Yes Yes Yes Partial yes 
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Bao, 20165 Yes Yes Yes Yes Yes Yes Yes Yes 
Beecham, 20156 Yes Yes No meta-
analysis 
No meta-
analysis 
No Yes No meta-
analysis 
No 
Cooper, 201714 Yes Yes No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Cooper, 201715 Yes Yes No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
No 
Cooper, 201713 N/A N/A No meta-
analysis 
No meta-
analysis 
N/A N/A No meta-
analysis 
Yes 
Cooper, 201712 N/A N/A No meta-
analysis 
No meta-
analysis 
N/A N/A No meta-
analysis 
Yes 
Cooper, 201711 N/A N/A No meta-
analysis 
No meta-
analysis 
N/A N/A No meta-
analysis 
Yes 
Eccleston, 201722 Yes Yes No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Hadley, 201335 Yes No Yes No Yes Yes No No 
Heintjes, 200437 Yes No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Kaminski, 201144 Yes Yes No meta-
analysis 
No meta-
analysis 
No No No meta-
analysis 
Yes 
Korterink, 201551 Yes No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Martin, 201756 Yes Yes No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Nicholson, 201765 Yes No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Quigley, 200370 No No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis  
No 
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Saps, 201576 Yes No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Schmidt-Hanswen, 201679 Yes Yes No meta-
analysis 
No meta-
analysis 
Yes No No meta-
analysis 
Yes 
Straube, 201483 Partial yes Yes No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Weydert, 200390 No No No meta-
analysis 
No meta-
analysis 
No No No meta-
analysis 
No 
Wiffen, 201791 N/A N/A No meta-
analysis 
No meta-
analysis 
N/A N/A No meta-
analysis 
Yes 
Wiffen, 201697 Yes No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Wiffen, 201795 Yes No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
Wiffen, 201793 Yes No No meta-
analysis 
No meta-
analysis 
Yes Yes No meta-
analysis 
Yes 
